Unlocking the Full Commercial Value of Breakthrough Biomedical Innovation
Some of the most important biomedical technologies in the market today originated from alliances between academia and industry. By speeding the flow of Harvard inventions through key development milestones, the Blavatnik Biomedical Accelerator serves as a catalyst for expanding and enriching these important alliances.
Our proven strategy of selecting projects with clear commercial potential and providing gap development funding and support provides important benefits to industry:
- Mature, investment-grade technologies
- Expedited product development lifecycles
- Reduced business risk
Guided by a team of experienced leaders from both research and business, the Blavatnik Biomedical Accelerator is committed to helping life science companies, venture firms, entrepreneurs, and other potential partners access Harvard's groundbreaking research innovation.
The Accelerator is an extraordinarily effective program aimed at translating early research discoveries with commercial potential into the next generation of therapeutics and other technologies. It expedites the process of converting discoveries into potentially lifesaving treatments.
Thomas Dudley Cabot Professor in the Natural Sciences at Harvard University and co-Director of Harvard Stem Cell Institute